Cipla Ltd has received an approval for its product Q-TIB from World Health Organization (WHO). Q-TIB is a novel fixed dose combination in a single tablet. This is the first time that such a combination has been made available in the world. Cipla will market the product globally.

Q-TIB will help prevent tuberculosis infection in people living with HIV who face a challenged immune system and are prone to opportunistic infections, which constitute the major source of premature deaths among them.


10 Diagnostic Imaging Trends for 2018

Best of 2017 Medical

 

Digital version